Veracyte (VCYT) Director Muna Bhanji Sells $81K of Stock

Veracyte, Inc. (NASDAQ:VCYT) director Muna Bhanji sold 1,864 shares of the company on October 19, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $43.70 each, for a total value of $81,456.80.

VCYT Veracyte, Inc.

$44.79 ▲ +5.66% year to date

1M 3M YTD

Daily close · Oct 20, 2026

Inside Muna Bhanji's VCYT Trade

The transaction was executed as part of a pre-planned trading schedule under Rule 10b5-1. Following the sale, Bhanji directly owns 40,854 shares of the diagnostics company, marking a 4.36% cut to this holding. On the day of the trade, Veracyte shares closed at $43.80.

Other Institutional Activity in Veracyte

Large funds continue to adjust their positions in the healthcare stock. ARK Investment Management reduced its holdings by 833,729 shares, ending the period with 3,053,818 shares worth about $179.3 million. Artisan Partners Limited Partnership grew its holdings by 41,774 shares, ending with 5,538,404 shares worth about $248.1 million. First Trust Advisors LP grew its holdings by 390,814 shares, ending with 2,507,902 shares worth about $112.3 million. ARK Investment Management, LLC cut 757,988 shares, leaving it with 2,295,951 shares valued at about $102.8 million.

Veracyte, Inc. Stock Up 2.3%

Shares recently traded around $44.79 as of October 20, 2026, putting the price up about 2.3% since the insider transaction. The stock has a market capitalization of roughly $3.60 billion and trades above both its 50-day moving average of $43.46 and its 200-day moving average of $42.60.

Recent Earnings

For investors following the business side, Veracyte posted $561.9 million in trailing-twelve-month revenue alongside earnings of $1.40 per share. The company reported a net profit margin of 20.4% and a return on equity of 8.8%. Revenue grew 15.5% over the prior year. The company's next quarterly financial update is scheduled for November 4, 2026.

Insider Buying and Selling at Veracyte, Inc.

Several other insiders trimmed their positions ahead of this transaction. Officer Phillip G Febbo sold 13,110 shares on September 4, 2026, valued at $564,410. Chief Financial Officer Rebecca Chambers sold 3,652 shares on September 4, 2026, worth $157,394. Director Jens Holstein sold 5,000 shares at $40.95 on September 14, 2026, for a total of $204,747. Officer John Leite sold 4,015 shares at $40.00 on September 21, 2026, worth $160,600.

Analysts Set New Price Targets

Wall Street firms maintain active coverage on the stock. Piper Sandler maintains an Overweight rating with a $54.00 price target as of August 4, 2026. Stephens & Co. maintains an Overweight rating with a $55.00 target on the same date. Morgan Stanley maintains an Underweight rating with a $44.00 target. UBS maintains a Buy rating with a $65.00 target on September 9, 2026. Freedom Capital Markets maintains a Buy rating with a $66.00 target on September 15, 2026. The stock carries a consensus buy recommendation from 12 analysts.

About Veracyte, Inc.

Veracyte operates as a healthcare diagnostics business based in South San Francisco, California. The company develops genomic tests that help doctors diagnose various cancers, including thyroid, prostate, bladder, and breast cancers, alongside lung cancer screening tools.

Bottom Line

Insiders continue regular sales while the company prepares for its next earnings release on November 4, 2026. Shareholders should watch upcoming SEC filings and financial results for further guidance on company performance.